A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland.
Saved in:
| Title: | A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland. |
|---|---|
| Authors: | Besson J; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland. Juliette.Besson@hotmail.com., Audran R; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland., Karlen M; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Miauton A; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Hajjami HM; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland., Warpelin-Decrausaz L; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland.; Research Support Unit, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Sene L; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland., Schaufelberger S; Information Systems and Digital Transformation, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Faivre V; Information Systems and Digital Transformation, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Faouzi M; Division of Biostatistics, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Hartley MA; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Spertini F; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland., Genton B; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland. |
| Source: | BMC infectious diseases [BMC Infect Dis] 2025 Apr 07; Vol. 25 (1), pp. 472. Date of Electronic Publication: 2025 Apr 07. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
